COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 838: Articles 8371-8380  | Next

Identification and Quantification of Bioactive Compounds Suppressing SARS-CoV-2 Signals in Wastewater-based Epidemiology Surveillance
Bayati, M., Hsieh, H.-Y., Hsu, S.-Y., Rogers, E., Belenchia, A., Zemmer, S. A., Blanc, T., LePage, C., Klutts, J., Reynolds, M., Semkiw, E., Johnson, H.-Y., Foley, T., Wieberg, C. G., Wenzel, J., Lyddon, T., LePique, M., Rushford, C., Salcedo, B., Young, K., Graham, M., Suarez, R., Ford, A., Lei, Z., Sumner, L., Mooney, B. P., Wei, X., Greenlief, C. M., Johnson, M., Lin, C.-H.
10.1101/2022.03.09.22272155 — Posted: 2022-03-12
Duration of vaccine effectiveness against SARS-CoV2 infection, hospitalisation, and death in residents and staff of Long-Term Care Facilities (VIVALDI): a prospective cohort study, England, Dec 2020-Dec 2021
Shrotri, M., Krutikov, M., Nacer-Laidi, H., Azmi, B., Palmer, T., Giddings, R., Fuller, C., Irwin-Singer, A., Baynton, V., Tut, G., Moss, P., Hayward, A., Copas, A., Shallcross, L.
10.1101/2022.03.09.22272098 — Posted: 2022-03-12
SARS-CoV-2 Omicron disease burden in Australia following border reopening: a modelling analysis
Milne, G. J., Carrivick, J.
10.1101/2022.03.09.22272170 — Posted: 2022-03-12
Interstitial lung damage following COVID-19 hospitalisation: an interim analysis of the UKILD Post-COVID study.
Stewart, I., Jacob, J., Gerorge, P., Molyneax, P., Porter, J., Allen, R., Baillie, J., Barratt, S., Beirne, P., Bianchi, S., Blaikley, J., Chalmers, J., Chambers, R., Chadhuri, N., Coleman, C., Collier, G., Denneny, E., Docherty, A., Elneima, O., Evans, R., Fabbri, L., Gibbons, M., Gleeson, F., Gooptu, B., Greening, N., Guillen Guio, B., Hall, I., Hanley, N., Harris, V., Harrison, E., Heightman, M., Hillman, T., Horsley, A., Houchen-Wolloff, L., Jarrold, I., Johnson, S., Jones, M., Khan, F., Lawson, R., Leavy, O., Lone, N., Marks, M., McAuley, H., Mehta, P., Omer, E., Parekh, D., Parmar, A., Piper Hanley, K., Plate, M., Pearl, J., Poinasamy, K., Quint, J., Raman, B., Richardson, M., Rivera-Ortega, P., Saunders, L., Saunders, R., Semple, M., Sereno, M., Shikotra, A., Simpson, A., Singapuri, A., Smith, D., Spears, M., Spencer, L., Stanel, S., Thickett, D., Thompson, A., Thorpe, M., Walsh, S., Walker, S., Weatherley, N., Weeks, M., Wild, J., Wootton, D., Brightling, C., Ho, L., Wain, L., Jenkins, R.
10.1101/2022.03.10.22272081 — Posted: 2022-03-12
Cross-sector Decision Landscape in Response to COVID-19: A Qualitative Analysis of North Carolina Decision-Makers
Biddell, C. B., Johnson, K., Patel, M. D., Smith, R., Hecht, H. K., Mayorga, M. E., Swann, J. L., Hassmiller Lich, K.
10.1101/2022.03.09.22272160 — Posted: 2022-03-12
Prevalence and Predictors of Depression, Anxiety and Stress among Elderly in the aftermath of COVID-19: A Quantitative Study from Central India
Malhotra, V., Javed, D., Bharshankar, R., Singh, V., Gautam, N., Mishra, S., Chundawat, D., Kushwah, A., Singh, G.
10.1101/2022.03.10.22272024 — Posted: 2022-03-12
Rare Variants in Inborn Errors of Immunity Genes Associated with Covid-19 Severity
Liu, P., Fang, M., Luo, Y., Zheng, F., Jin, Y., Cheng, F., Zhu, H., Jin, X.
10.1101/2022.03.09.22270766 — Posted: 2022-03-12
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
Dougan, M., Azizad, M., Chen, P., Feldman, B., Frieman, M., Igbinadolor, A., Kumar, P. N., Morris, J., Potts, J., Baracco, L., Macpherson, L., Kallewaard, N., Patel, D., Hufford, M. M., Wietecha, L., Chigutsa, E., Demmon, S. L., Jones, B. E., Nirula, A., Skovronsky, D., Williams, M., Gottlieb, R. L.
10.1101/2022.03.10.22272100 — Posted: 2022-03-12
Possible Role of P-selectin Adhesion in Long-COVID: A Comparative Analysis of a Long-COVID Case Versus an Asymptomatic Post-COVID Case
Tarasev, M., Gao, X., Mota, S., Ferranti, M., Zaidi, A. U., Hannan, B., Hines, P.
10.1101/2022.03.09.22271297 — Posted: 2022-03-12
SARS-CoV-2 seroconversion in response to infection and vaccination: A time series local study in Brazil
Huergo, L., Paula, N. M., Goncalves, A. C. A., Kluge, C. H. S., Martins, P. H. S. A., Camargo, H. S. C., Santana, T. P., Farias, L. R. P., Lima, E. S., Aldrighi, J. D., Jacotenski, G. T., Vargas, L. R., Costa, G., Weissheimer, K. V., Nazario, M. G., Teixeira, K. N., Conzentino, M. d. S.
10.1101/2022.03.10.22271805 — Posted: 2022-03-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).